Steroid Minimization in Adults with Minimal Change Disease

BACKGROUND: Minimal change disease (MCD) causes approximately 10% of nephrotic syndrome in adults. While glucocorticoids (GCs) effectively induce remission in MCD, the disease has a high relapse rate (50–75%), and repeated exposure to GCs is often required. The adverse effects of GCs are well recogn...

Descripción completa

Detalles Bibliográficos
Autores principales: Koirala, Abbal, Jefferson, J. Ashley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677715/
https://www.ncbi.nlm.nih.gov/pubmed/36751385
http://dx.doi.org/10.1159/000517626
Descripción
Sumario:BACKGROUND: Minimal change disease (MCD) causes approximately 10% of nephrotic syndrome in adults. While glucocorticoids (GCs) effectively induce remission in MCD, the disease has a high relapse rate (50–75%), and repeated exposure to GCs is often required. The adverse effects of GCs are well recognized and commonly encountered with the high doses and recurrent courses used in MCD. SUMMARY: In this review, we will discuss the standard therapy of MCD in adults and then describe new therapeutic options in induction therapy and treatment of relapses in MCD, minimizing the exposure to GCs. KEY MESSAGES: Steroid minimization strategies may decrease adverse effects in the treatment of MCD.

Ejemplares similares